Clemens Fischer

Since founding FUTRUE, Clemens has pursued transformative medicines and technologies through agile, specialized companies, recently reaching a key milestone with the cannabinoid-based pain medication VER-01 toward his vision of a world without chronic pain. As early as 2011, with today’s market leader Kijimea Reizdarm, he brought the first probiotic medical product for the treatment of irritable bowel syndrome to market. Through FUTRUE Research & Science, a specialized research service provider, Clemens is pursuing the ambitious goal of halving the development time of new therapies. Clemens holds a master’s degree in business economics and business administration from Harvard University, as well as a medical license (Approbation) and a doctorate in medicine from the Technical University of Munich.

‍